Comparable stake leader
BlackRock, Inc.
SEC ownership of Terns Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001831363.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Parsed ownership sources
-
13F, 13D/G, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
BlackRock, Inc.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
50 of 50
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
BlackRock, Inc.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
31 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001831363
- Issuer location
- Foster City, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Terns Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
BlackRock, Inc.
Disclosed value leader
BlackRock, Inc.
Comparable rows
50/50
Latest evidence
31 Mar 2026
13F
13D/G
3/4/5
Lead comparable stake: 6.8%
13D/G row: BlackRock, Inc.
Showing 1-8 of 50 holder rows.
Quick read
BlackRock, Inc. leads the comparable SEC ownership view at 6.8%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens BlackRock, Inc.'s linked filing trail.
Comparable ownership
Top 5
BlackRock, Inc.
6.8%
Schonfeld Strategic Advisors LLC
4.9%
ORBIMED ADVISORS LLC
4.8%
CITADEL ADVISORS LLC
4.1%
Deep Track Capital, LP
3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
Company
|
6.8%
from 13D/G
|
$504,508,547
9,569,585 shares
|
— | 31 Mar 2026 |
| Schonfeld Strategic Advisors LLC |
13D/G
13F
Company
|
4.9%
|
$12,571,196
4,305,204 shares
|
-$2,713,568 | 31 Mar 2025 |
| ORBIMED ADVISORS LLC |
13D/G
3/4/5
Director, 10%+ Owner
|
4.8%
|
$31,842,911
4,240,068 shares
|
$0 | 03 Nov 2025 |
| CITADEL ADVISORS LLC |
13F
13D/G
Company · Kenneth Griffin
|
4.1%
from 13D/G
|
$169,695,663
3,218,810 shares
|
— | 31 Mar 2026 |
| Deep Track Capital, LP |
13D/G
13F
Company
|
3%
|
$111,762,000
3,150,000 shares
|
-$154,160,600 | 31 Dec 2025 |
| Vivo Opportunity Fund Holdings, L.P. |
13D/G
|
2.5%
|
$95,817,820
2,700,615 shares
|
$0 | 31 Jan 2025 |
| Adage Capital Management, L.P. |
13D/G
|
1.8%
|
$111,829,119
2,124,817 shares
|
-$180,267,381 | 31 Mar 2026 |
| Commodore Capital LP |
13D/G
|
1.4%
|
$52,333,000
1,475,000 shares
|
-$149,903,000 | 31 Dec 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$7,062,533.
Buys
$0
Insiders: 0
Sells
$7,062,533
Insiders: 3
Net
-$7,062,533
Shares: -196,815
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 196,815
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 30,108 | $0 | $1,302,380 | -$1,302,380 |
| 6-9 | 0 | 165,763 | $0 | $5,752,745 | -$5,752,745 |
| 9-12 | 0 | 944 | $0 | $7,407 | -$7,407 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 22 reporting-owner rows connected to Terns Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
22
Largest Forms 3/4/5 holder
Vivo Opportunity, LLC
Net 12M change
-$7,062,532
Latest report
05 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Vivo Opportunity, LLC | 10%+ Owner | $38,671,440 | Filing P/S | 01 Apr 2024 | ||
| Carl L. Gordon | Director, 10%+ Owner | $7,556,350 | Filing P/S | 15 Jul 2024 | ||
| ORBIMED ADVISORS LLC | Director, 10%+ Owner | $7,556,350 | Filing P/S | 15 Jul 2024 | ||
| Hongbo Lu | Director | $4,999,995 | Filing P/S | 11 Jun 2025 | ||
| LAV Biosciences Fund V, L.P. | 10%+ Owner | $2,002,500 | Mixed | 23 Nov 2022 | ||
| David Eric Strauss | Principal Accounting Officer | $519,682 | Mixed | 01 Feb 2025 | ||
| Mark J. Vignola | Chief Financial Officer | $433,210 | Filing P/S | 02 Jan 2025 | ||
| Seokho Bryan Yoon | COO and General Counsel | $408,214 | Filing P/S | 31 May 2024 | ||
| Erin Quirk | President, Head of R&D | $283,500 | Mixed | 23 Jan 2024 | ||
| Senthil Vel Sundaram | Chief Executive Officer, Director | $36,931 | Mixed | 31 May 2023 | ||
| Melita Sun Jung | Chief Business Officer | $11,498 | Filing P/S | 30 Jan 2025 | ||
| Jill M. Quigley | Director | $0 | -$441,360 | -100% | Mixed | 05 May 2026 |
| Amy L. Burroughs | Chief Executive Officer, Director | $0 | -$6,519,520 | -100% | Mixed | 05 May 2026 |
| Emil Kuriakose | Chief Medical Officer | $0 | -$101,652 | -100% | Mixed | 05 May 2026 |
| Andrew Gengos | Chief Financial Officer | $0 | Mixed | 05 May 2026 | ||
| Radhika Tripuraneni | Director | Mixed | 05 May 2026 | |||
| Heather D. Turner | Director | Mixed | 05 May 2026 | |||
| Robert Azelby | Director | Mixed | 05 May 2026 | |||
| David A. Fellows | Director | Mixed | 05 May 2026 | |||
| Jeffrey B. Kindler | Director | Mixed | 05 May 2026 |
Recent insider transactions for Terns Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Robert Azelby | TERN | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -91,697 | 0 | 05 May 2026 | Direct | ||
| Heather D. Turner | TERN | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -110,697 | 0 | 05 May 2026 | Direct | ||
| Radhika Tripuraneni | TERN | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -158,030 | 0 | 05 May 2026 | Direct | ||
| Jill M. Quigley | TERN | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -115,309 | 0 | 05 May 2026 | Direct | ||
| Jeffrey B. Kindler | TERN | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -144,505 | 0 | 05 May 2026 | Direct | ||
| David A. Fellows | TERN | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -157,136 | 0 | 05 May 2026 | Direct | ||
| Emil Kuriakose | TERN | Common Stock | Disposed to Issuer | -100% | -81,953 | 0 | 05 May 2026 | Direct | ||
| Emil Kuriakose | TERN | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -24,562 | 0 | 05 May 2026 | Direct | ||
| Emil Kuriakose | TERN | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -1,115,000 | 0 | 05 May 2026 | Direct | ||
| Andrew Gengos | TERN | Common Stock | Disposed to Issuer | -100% | -68,750 | 0 | 05 May 2026 | Direct | ||
| Andrew Gengos | TERN | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -40,503 | 0 | 05 May 2026 | Direct | ||
| Andrew Gengos | TERN | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -887,500 | 0 | 05 May 2026 | Direct | ||
| Amy L. Burroughs | TERN | Common Stock | Disposed to Issuer | -100% | -150,000 | 0 | 05 May 2026 | Direct | ||
| Amy L. Burroughs | TERN | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -8,319 | 0 | 05 May 2026 | Trust | ||
| Amy L. Burroughs | TERN | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -146,614 | 0 | 05 May 2026 | Direct | ||
| Amy L. Burroughs | TERN | Stock Option (Right to Buy) | Disposed to Issuer | -100% | -2,505,534 | 0 | 05 May 2026 | Direct | ||
| Emil Kuriakose | TERN | Common Stock | Sale | -0.88% | $49,693 | $52.75 | -942 | 105,673 | 01 Apr 2026 | Direct |
| Amy L. Burroughs | TERN | Common Stock | Sale | -4.8% | $681,108 | $46.71 | -14,583 | 288,976 | 16 Mar 2026 | Direct |
| Amy L. Burroughs | TERN | Common Stock | Options Exercise | 5.05% | 14,583 | 303,559 | 16 Mar 2026 | Direct | ||
| Amy L. Burroughs | TERN | Stock Option (Right to Buy) | Options Exercise | -1.5% | -14,583 | 955,534 | 16 Mar 2026 | Direct | ||
| Amy L. Burroughs | TERN | Common Stock | Sale | -4.8% | $571,579 | $39.19 | -14,583 | 288,976 | 17 Feb 2026 | Direct |
| Amy L. Burroughs | TERN | Common Stock | Options Exercise | 5.05% | 14,583 | 303,559 | 17 Feb 2026 | Direct | ||
| Amy L. Burroughs | TERN | Stock Option (Right to Buy) | Options Exercise | -1.48% | -14,583 | 970,117 | 17 Feb 2026 | Direct | ||
| Jill M. Quigley | TERN | Stock Option (Right to Buy) | Award | 1,697 | 1,697 | 01 Feb 2026 | Direct | |||
| Radhika Tripuraneni | TERN | Stock Option (Right to Buy) | Award | 1,697 | 1,697 | 01 Feb 2026 | Direct | |||
| Robert Azelby | TERN | Stock Option (Right to Buy) | Award | 1,697 | 1,697 | 01 Feb 2026 | Direct | |||
| Heather D. Turner | TERN | Stock Option (Right to Buy) | Award | 1,697 | 1,697 | 01 Feb 2026 | Direct | |||
| Jeffrey B. Kindler | TERN | Stock Option (Right to Buy) | Award | 1,697 | 1,697 | 01 Feb 2026 | Direct | |||
| David A. Fellows | TERN | Stock Option (Right to Buy) | Award | 2,828 | 2,828 | 01 Feb 2026 | Direct | |||
| Amy L. Burroughs | TERN | Common Stock | Sale | -19.2% | $2,548,603 | $37.07 | -68,749 | 288,976 | 15 Jan 2026 | Direct |
| Amy L. Burroughs | TERN | Common Stock | Options Exercise | 23.8% | 68,749 | 357,725 | 15 Jan 2026 | Direct | ||
| Amy L. Burroughs | TERN | Stock Option (Right to Buy) | Options Exercise | -6.53% | -68,749 | 984,700 | 15 Jan 2026 | Direct | ||
| Emil Kuriakose | TERN | Common Stock | Award | 111.7% | 56,250 | 106,615 | 14 Jan 2026 | Direct | ||
| Emil Kuriakose | TERN | Stock Option (Right to Buy) | Award | 112,500 | 112,500 | 14 Jan 2026 | Direct | |||
| Andrew Gengos | TERN | Common Stock | Award | 208.1% | 68,750 | 101,788 | 14 Jan 2026 | Direct | ||
| Andrew Gengos | TERN | Stock Option (Right to Buy) | Award | 137,500 | 137,500 | 14 Jan 2026 | Direct | |||
| Amy L. Burroughs | TERN | Common Stock | Award | 107.9% | 150,000 | 288,976 | 14 Jan 2026 | Direct | ||
| Amy L. Burroughs | TERN | Stock Option (Right to Buy) | Award | 300,000 | 300,000 | 14 Jan 2026 | Direct | |||
| Amy L. Burroughs | TERN | Common Stock | Sale | -33.9% | $2,718,230 | $38.10 | -71,339 | 138,976 | 05 Jan 2026 | Direct |
| Amy L. Burroughs | TERN | Common Stock | Options Exercise | 248.7% | 150,000 | 210,315 | 05 Jan 2026 | Direct | ||
| Amy L. Burroughs | TERN | Restricted Stock Unit | Options Exercise | -100% | -150,000 | 0 | 05 Jan 2026 | Direct | ||
| Amy L. Burroughs | TERN | Common Stock | Options Exercise | 55.6% | 21,551 | 60,315 | 02 Jan 2026 | Direct | ||
| Amy L. Burroughs | TERN | Stock Option (Right to Buy) | Options Exercise | -2% | -21,551 | 1,053,449 | 02 Jan 2026 | Direct | ||
| Emil Kuriakose | TERN | Common Stock | Sale | -2.24% | $44,552 | $38.57 | -1,155 | 50,365 | 02 Jan 2026 | Direct |
| Jill M. Quigley | TERN | Common Stock | Sale | -100% | $441,360 | $18.00 | -24,520 | 0 | 04 Nov 2025 | Direct |
| Jill M. Quigley | TERN | Common Stock | Options Exercise | 24,520 | 24,520 | 04 Nov 2025 | Direct | |||
| Jill M. Quigley | TERN | Stock Option (Right to Buy) | Options Exercise | -86.1% | -24,520 | 3,955 | 04 Nov 2025 | Direct | ||
| Emil Kuriakose | TERN | Common Stock | Sale | -1.8% | $7,407 | $7.85 | -944 | 51,520 | 01 Oct 2025 | Direct |
* marks a reported price that did not pass the local price check.